Paricalcitol Capsule for Secondary Hyperparathyroidism in Stage 3/4 Chronic Kidney Disease: A Randomised Multicentre, Double-blind, Placebo-controlled Phase 3 Clinical Trial
Introduction: Paricalcitol is a synthetic, selective vitamin D receptor activator, as a potential treatment for patients in chronic kidney disease (CKD) with secondary hyperparathyroidism (SHPT). Paricalcitol capsule (HR081702) offers a convenient dose form for patients. The study evaluated the efficacy and safety of HR081702 in stages 3 and 4 CKD patients with SHPT in China. Methods: In this multicentre, randomised, double-blind, placebo-controlled phase 3 trial (ClinicalTrials.gov, NCT04994080), patients (aged ≥18 years) with stage 3 and 4 CKD and SHPT were enrolled if the mean of two consecutive intact parathyroid hormone (iPTH) measurements was ≥150 pg/mL, the serum calcium level was between 8.0 and 10.0 mg/dL (1.99 and 2.50 mmol/L), and serum phosphorus level was ≤5.2 mg/dL (1.68 mmol/L). Eligible patients were randomised (2:1) to receive HR081702 or placebo orally once a day for 24 weeks. Dose adjustments were primarily based on iPTH levels and were guided by serum calcium and phosphorous levels. The primary endpoint was the proportion of patients to achieve at least two consecutive iPTH reductions of ≥30% from baseline within 24 weeks of treatment. Results: A total of 90 patients were randomised to the HR081702 group (n=60) or the placebo group (n=30). After 24 weeks treatment, 91.7% of patients (55/60) in the HR081702 group achieved the primary endpoint, compared with 16.7% of patients (5/30) in the placebo group (difference, 75.0% [95% CI, 59.9 to 90.1]; P<0.0001). Furthermore, at least four consecutive reductions of ≥30% in iPTH levels from baseline were observed in 68.3% of HR081702-treated patients, compared with 6.7% of placebo-treated patients. Treatment-related adverse events (TRAEs) were reported in 50.0% of patients receiving HR081702 and 26.7% of patients in the placebo group; all TRAEs were mild or moderate in severity. Hyperphosphatemia was the most common TRAE (20.0% in the HR081702 group and 6.7% in the placebo group). Conclusion: Paricalcitol capsule (HR081702) is a safe and effective treatment option for stages 3 and 4 CKD patients with SHPT, significantly reducing iPTH levels.
Authors
- Zhou Linghui
- Wenxiu Chang (ORCID: https://orcid.org/0000-0001-6269-5694)
- 刘昌华
- Lihua Wang (ORCID: https://orcid.org/0000-0001-9908-2816)
- Jianghua Chen (ORCID: https://orcid.org/0000-0001-5958-8177)
- Wanhong Lu
- Xiao-Yong Yu
- Yanning Zhang
- Hua Zhou
- ping luo
- Chaosheng Chen
- Jun Cheng
- Xiaoying Du
- Wenbin Li
- Hong-Li Lin
- Lingling Xu
- Xiaoyi Sun
Institutions
- Shanxi Medical University (CN)
- Jilin University (CN)
- Wenzhou Medical University (CN)
- Tianjin First Center Hospital (CN)
- Sheng Jing Hospital (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- General Hospital of Shenyang Military Region (CN)
- Second Hospital of Shanxi Medical University (CN)
- Northern Jiangsu People's Hospital (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
- Second Affiliated Hospital of Jilin University (CN)
- Shaanxi Provincial Hospital of Traditional Chinese Medicine (CN)
- Jiangsu Hengrui Medicine (China) (CN)
- Shandong First Medical University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Kidney Diseases
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1159/kdd/adkag010
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00